Movement Alert｜10x Genomics Rises 5.27% in Regular Trading, BofA Securities Raises Price Target to $46

Market Focus07-14 22:22

On July 14, 10x Genomics rose 5.27% in regular trading, trading at $44.05/share, with turnover of $21.35 million. The move was driven by BofA Securities significantly raising its price target on the stock from $30 to $46, representing a 53% upward revision and well above the Street consensus target of $25.77.

The bullish call comes amid improving fundamentals. The company reported Q1 EPS of -$0.10, beating the consensus estimate of -$0.30 by 66.67%, while revenue of $150.8 million also topped the $146.4 million estimate. The loss-narrowing trajectory remains intact, with full-year revenue guidance set at $600 million to $625 million. Additionally, the company recently completed its acquisition of Proteintech Genomics to expand proteomics capabilities and established a collaboration with the Cleveland Clinic to advance single-cell and spatial technologies in bladder cancer diagnostics, broadening its commercial pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180248560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180248560","market":"hk","top_or_hot":-1,"title":"Movement Alert｜10x Genomics Rises 5.27% in Regular Trading, BofA Securities Raises Price Target to $46","media":"Market Focus","content":"<p><p>On July 14, 10x Genomics rose 5.27% in regular trading, trading at $44.05/share, with turnover of $21.35 million. The move was driven by BofA Securities significantly raising its price target on the stock from $30 to $46, representing a 53% upward revision and well above the Street consensus target of $25.77.</p><p>The bullish call comes amid improving fundamentals. The company reported Q1 EPS of -$0.10, beating the consensus estimate of -$0.30 by 66.67%, while revenue of $150.8 million also topped the $146.4 million estimate. The loss-narrowing trajectory remains intact, with full-year revenue guidance set at $600 million to $625 million. Additionally, the company recently completed its acquisition of Proteintech Genomics to expand proteomics capabilities and established a collaboration with the Cleveland Clinic to advance single-cell and spatial technologies in bladder cancer diagnostics, broadening its commercial pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜10x Genomics Rises 5.27% in Regular Trading, BofA Securities Raises Price Target to $46</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜10x Genomics Rises 5.27% in Regular Trading, BofA Securities Raises Price Target to $46\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, 10x Genomics rose 5.27% in regular trading, trading at $44.05/share, with turnover of $21.35 million. The move was driven by BofA Securities significantly raising its price target on the stock from $30 to $46, representing a 53% upward revision and well above the Street consensus target of $25.77.</p><p>The bullish call comes amid improving fundamentals. The company reported Q1 EPS of -$0.10, beating the consensus estimate of -$0.30 by 66.67%, while revenue of $150.8 million also topped the $146.4 million estimate. The loss-narrowing trajectory remains intact, with full-year revenue guidance set at $600 million to $625 million. Additionally, the company recently completed its acquisition of Proteintech Genomics to expand proteomics capabilities and established a collaboration with the Cleveland Clinic to advance single-cell and spatial technologies in bladder cancer diagnostics, broadening its commercial pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1180248560","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180248560","pubTimestamp":1784038921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, 10x Genomics rose 5.27% in regular trading, trading at $44.05/share, with turnover of $21.35 million. The move was driven by BofA Securities significantly raising its price target on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"走势警报|10x Genomics常规交易上涨5.27%，美国银行证券将目标价上调至46美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"On July 14, 10x Genomics rose 5.27% in regular trading, trading at $44.05/share, with turnover of $21.35 million. The move was driven by BofA Securities significantly raising its price target on the stock from $30 to $46, representing a 53% upward revision and well above the Street consensus target of $25.77.The bullish call comes amid improving fundamentals. The company reported Q1 EPS of -$0.10, beating the consensus estimate of -$0.30 by 66.67%, while revenue of $150.8 million also topped the $146.4 million estimate. The loss-narrowing trajectory remains intact, with full-year revenue guidance set at $600 million to $625 million. Additionally, the company recently completed its acquisition of Proteintech Genomics to expand proteomics capabilities and established a collaboration with the Cleveland Clinic to advance single-cell and spatial technologies in bladder cancer diagnostics, broadening its commercial pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180248560","isCrawlerRequest":true}